-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30

Benzinga·05/28/2026 14:06:28
Listen to the news
Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and raises the price target from $12 to $30.